-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Two Projects and One Individual from Shijiazhuang Sihua Pharmaceutical Group Awarded the “Quality Management Craftsmanship Project” Award by the China Association for Pharmaceutical Quality Management
Category:
发布时间：2025-10-16
【概要描述】
On October 16, at the 2025 Academic Annual Conference of the China Association for Pharmaceutical Quality Management held in Tonghua, Jilin Province, exciting news was announced: the highly anticipated “China Pharmaceutical Industry Quality Management Craftsmanship” awards were officially presented. Shijiazhuang Sihua Pharmaceutical Co., Ltd. emerged as a standout winner, securing three prestigious honors—the “2024 Quality Management Craftsmanship Achievement Award” in two categories and the “Quality Management Craftsmanship Figure Award”—thanks to its exceptional quality management practices and unwavering commitment to innovation.
On October 16, at the 2025 Academic Annual Conference of the China Association for Pharmaceutical Quality Management held in Tonghua, Jilin Province, exciting news was announced: the highly anticipated “Artisan Excellence in Pharmaceutical Quality Management” awards were officially presented. Shijiazhuang Sihua Pharmaceutical Co., Ltd. was honored with three prestigious awards—two “Artisan Achievements in Quality Management” and one “Artisan Figure in Quality Management”—in recognition of its outstanding quality management practices and relentless spirit of innovation.
This time, the Group was honored with the “Quality Management Excellence Award” for two achievements: “Improvement of Peritoneal Dialysis Solution Product Quality” and “Establishment and Application of the 21235 Risk Control Model for Parameter-Based Release.” From project initiation and planning through to implementation, both initiatives have consistently upheld the core principle of “quality first,” vividly demonstrating the seamless integration of the company’s quality management system with innovative technologies. In particular, the peritoneal dialysis solution project underwent two years of meticulous refinement, during which Shijiazhuang Sihua Pharmaceutical’s production, technical, and quality teams pursued excellence in every detail and rigorously controlled each stage of the manufacturing process, ultimately delivering a product that has earned widespread clinical trust and achieving simultaneous improvements in quality metrics and market share. Meanwhile, the parameter-based release project focused on the production of the company’s flagship high-volume injectables and systematically established a comprehensive, end-to-end quality risk-control framework. The standardized production processes it developed not only provide a robust theoretical foundation for the full-scale implementation of the CCS system but also significantly enhance production efficiency and product quality. This project previously won the National Quality Benchmark Award in 2023, and its latest recognition further underscores its status as a benchmark achievement.
Complementing the two Achievement Awards, Zhang Xu from the Group’s Quality Management Center was honored with the 2024 “Quality Management Artisan” Award in recognition of his outstanding contributions to quality management and his relentless pursuit of excellence.
According to reports, the “Artisan Spirit in Pharmaceutical Quality Management” award is designed to recognize organizations and individuals nationwide who have made outstanding contributions to pharmaceutical quality management and improvement, and is one of the most influential awards in the industry’s quality sector. The fact that two projects and two individuals from the Group have now received this honor signifies that the company has advanced to the forefront of the industry in terms of quality management, innovation capability, and the development of a high-caliber quality workforce.
“This weighty honor is both an encouragement and a call to action, belonging to every ‘Four-Pharmaceuticals’ employee who has quietly dedicated themselves to enhancing the company’s quality.” According to the group’s leader, the next step will be to further deepen comprehensive quality management, uphold the spirit of craftsmanship, continuously drive quality transformation and innovation, strive to create greater value for customers and society, and endeavor to contribute more wisdom and strength to the building of a Healthy China.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091